Lenalidomide Maintenance Therapy in Patients With MDS [myelodysplastic syndromes] or AML [acute myeloid leukaemia] With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation

Trial Profile

Lenalidomide Maintenance Therapy in Patients With MDS [myelodysplastic syndromes] or AML [acute myeloid leukaemia] With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms LENAMAINT
  • Most Recent Events

    • 21 Jul 2012 Actual end date (7 Jan 2011) added as reported by European Clinical Trials Database.
    • 21 Jul 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-002433-37).
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003747).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top